Tag: SDH-deficient
New Drug Shows Promise for Rare Gastrointestinal Tumors in Phase 2 Trial
A phase 2 trial shows rogaratinib, an FGFR inhibitor, demonstrates encouraging efficacy in patients with SDH-deficient GIST. The study represents…
Submit Your Paper to GMJ
No APC until January 2027.